Sustained DFS benefit with adjuvant pembrolizumab in high-risk RCC

Press/Media

Period	Feb 22 2022

Media coverage

Title	Sustained DFS benefit with adjuvant pembrolizumab in high-risk RCC
Media name/outlet	MedWire News
Country/Territory	United Kingdom
Date	02/22/22
URL	https://www.medwirenews.com/oncology/kidney-cancer/keynote-564-dfs-benefit-adjuvant-pembrolizumab-high-risk-rcc/20155644
Persons	Daniel Geynisman